Skip to content

Exagen Inc. XGN Class of Warrant or Right, Outstanding

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s class of warrant or right, outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s class of warrant or right, outstanding?
Exagen Inc. (XGN) reported class of warrant or right, outstanding of $131 in Q1 2026.
How has Exagen Inc.'s class of warrant or right, outstanding changed year-over-year?
Exagen Inc.'s class of warrant or right, outstanding decreased by 100.0% year-over-year, from $1.13M to $131.
What is the long-term trend for Exagen Inc.'s class of warrant or right, outstanding?
Over 5 years (2020 to 2025), Exagen Inc.'s class of warrant or right, outstanding has grown at a 13.9% compound annual growth rate (CAGR), from $426.83K to $819.36K.